Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GS-5885

Known as: GS 5885, GS5885, WHO 9796 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
A new class of highly potent NS5A inhibitors with an unsymmetric benzimidazole-difluorofluorene-imidazole core and distal [2.2.1… Expand
Is this relevant?
2014
2014
GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
GS-5885 is a novel hepatitis C virus (HCV) NS5A inhibitor. In a 3-day monotherapy study in treatment-naive genotype 1a (GT1a) and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND & AIMS GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent suppression of genotype… Expand
Is this relevant?
2012
2012
Background & Aims: GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent suppression of… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?